Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 9Gastrointestinal 5Thoracic 4Breast 4Genitourinary 3Dermatologic 3Head & Neck 2CNS 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Nasopharyngeal Neoplasms 1Epstein-Barr Virus Infections 1Anal Canal Carcinoma 1

Interventions

Cisplatin 263Radiotherapy 166Cetuximab 159Docetaxel 105Fluorouracil 104pembrolizumab 94Radiotherapy, Intensity-Modulated 83Carboplatin 80Paclitaxel 73Nivolumab 59Erlotinib Hydrochloride 35Surveys and Questionnaires 32Gemcitabine 32durvalumab 30Radiation 29Drug Therapy 25Immunohistochemistry 21Gefitinib 21Capecitabine 21tremelimumab 18Bevacizumab 18Surgical Procedures, Operative 17Sorafenib 17Magnetic Resonance Spectroscopy 17Ipilimumab 17Pemetrexed 16lenvatinib 15atezolizumab 15Radiosurgery 15Gene Expression Profiling 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Vaccines × Head & Neck × Clear all
NCT03946358 2024-12-20

VolATIL

Centre Hospitalier Universitaire de Besancon

Phase 2 Completed
47 enrolled
GastrointestinalGynecologicHead & Neck

Anal Canal Carcinoma, Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms

NCT01094405 2021-07-28

Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy

Chinese University of Hong Kong

Phase 2 Completed
25 enrolled
Head & Neck

Nasopharyngeal Neoplasms, Recurrence, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡